Aqua Bio Technology ASA: Subsequent Offering Start of Subscription Period

12 Mar 2026 07:45 CET

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR
INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED
STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR
DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER
OF ANY OF THE SECURITIES DESCRIBED HEREIN

Reference is made to the stock exchange announcement by Aqua Bio Technology
ASA ("ABTEC" or the "Company") on 11 March 2026 regarding the terms of a
subsequent offering of new shares in the Company (the "Subsequent Offering").

The Subsequent Offering consists of an offering of up to 800,000 new shares in
the Company (the "Offer Shares") directed towards the shareholders of the
Company as of 12 February 2026 (as registered in the VPS on 16 February 2026)
(the "Record Date"), except: (i) shareholders who were allocated shares in the
Private Placement, and (ii) shareholders who are resident in a jurisdiction
where such offering would be unlawful, or would require any prospectus filing,
registration or similar action (the "Eligible Shareholders"). The subscription
price per Offer Share is NOK 5.00 (the "Subscription Price").

In addition, the following types of investors shall have a secondary right to
subscribe for the Offer Shares: (i) ABTEC shareholders and other investors who
participated in the Private Placement, and (ii) other subscribers without
Subscription Rights (jointly, the "Secondary Subscribers") subject to a
minimum allocation of NOK 50,000. The Secondary Subscribers may subscribe for
Offer Shares that have not been subscribed and allocated to Eligible
Shareholders.

The Eligible Shareholders will be granted 0.0103 non-tradable subscription
rights to be used for subscription of Offer Shares (the "Subscription Rights")
for each existing share registered as held by such Eligible Shareholder as of
the Record Date, rounded down to the nearest whole number of Subscription
Rights. The number of Subscription Rights granted has been calculated based on
the number of shares outstanding in the Company prior to completion of the
reverse share split completed in February 2026. Each whole Subscription Right
provides a preferential right to subscribe for, and be allocated, one Offer
Share at the Subscription Price.

Over-subscription will be permitted.

Subscription without Subscription Rights will not be permitted, other than by
Secondary Subscribers.

The subscription period in the Subsequent Offering commences today, on 12
March 2026 at 09:00 hours (CET) and will end on 19 March 2026 at 16:30 hours
(CET). Subscription Rights that are not used to subscribe for Offer Shares
before 16:30 hours (CET) on 19 March 2026 will have no value and will lapse
without compensation to the holder.

An invitation letter (the "Invitation Letter") has been prepared in connection
with the Subsequent Offering, which sets out the terms and conditions for the
Subsequent Offering and includes a description of certain risk factors
pertaining to the Company, its shares and the Subsequent Offering.

Subscriptions by Eligible Shareholders may be made through the VPS' online
subscription system, or by correctly completing and signing the subscription
form included in the Invitation Letter. Eligible Shareholders who are
residents of Norway with a Norwegian national identity number, and Norwegian
private/public limited companies (AS/ASA), may be made electronically through
an online subscription system through a link available on the Company's
website https://aquabiotechnology.com/press-releases/. Subscription Rights
that are not used to subscribe for Offer Shares before the expiry of the
subscription period will have no value and will lapse without compensation to
the holder.

The Invitation Letter is attached hereto and will also be made available at
websites of the Company, on www.aquabiotechnology.com. Further information on
the Subsequent Offering is also available from the Company's stock exchange
notice dated 11 March 2026.


IMPORTANT INFORMATION
This announcement is not an offer to sell or a solicitation of offers to
purchase or subscribe for shares. Copies of this announcement may not be sent
to jurisdictions, or distributed in or sent from jurisdictions, in which this
is barred or prohibited by law. The information contained herein shall not
constitute an offer to sell or the solicitation of an offer to buy, in any
jurisdiction in which such offer or solicitation would be unlawful absent
registration, or an exemption from registration or qualification under the
securities laws of any jurisdiction.

This document is not for publication or distribution in, directly or
indirectly, Australia, Canada, Japan, Hong Kong or the United States or any
other jurisdiction in which such release, publication or distribution would be
unlawful, and it does not constitute an offer or invitation to subscribe for
or purchase any securities in such countries or in any other jurisdiction. In
particular, the document and the information contained herein should not be
distributed or otherwise transmitted into the United States or to publications
with a general circulation in the United States of America.

This announcement is not an offer for sale of securities in the United States.
Securities may not be offered or sold in the United States absent registration
with the United States Securities and Exchange Commission or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the
"Securities Act"). The Company does not intend to register any part of the
offering in the United States or to conduct a public offering in the United
States of the shares to which this document relates. This announcement is for
information purposes only and is not to be relied upon in substitution for the
exercise of independent judgment. It is not intended as investment advice and
under no circumstances is it to be used or considered as an offer to sell, or
a solicitation of an offer to buy any securities or a recommendation to buy or
sell any securities of the Company.

This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect
current expectations and assumptions as to future events and circumstances
that may not prove accurate. A number of material factors could cause actual
results and developments to differ materially from those expressed or implied
by these forward-looking statements.

The Company expressly disclaims any obligation or undertaking to update,
review or revise any statement contained in this announcement whether as a
result of new information, future developments or otherwise.

Contacts
Kristian Flaten
CEO & CFO
Aqua Bio Technology ASA

Phone: +47 9509 2322
Email: kf@aquabiotech.no

About Us
Aqua Bio Technology ASA (ABTEC) is a technology and distribution group in
skincare and nonfood. The group has distribution towards B2C and B2B, and
offers freight, customs, and logistics services. The group also develops
sustainable biotechnology for use in skincare products. Aqua Bio Technology is
listed on Euronext Expand Oslo.

This notice is published by Kristian Flaten on the listed date and time.

This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR. The information was submitted for publication, through the
agency of the contact persons set out above, at 2026-03-12 07:45 CET.

More information:
Access the news on Oslo Bors NewsWeb site

668076_260312 ABTEC Invitation Letter SO.pdf
668076_Aqua Bio Technology ASA- Subsequent Offering Start of Subscription Period.pdf